Osieka R
Medizinische Klinik IV, Medizinischen Fakultät der RWTH Aachen.
Zentralbl Chir. 1998;123(6):714-21.
Recent data on cancer mortality call for a reallocation of resources from searching for new treatments of advanced disease to preventive strategies. Vaccination against HBV or other infectious agents predisposing to cancer has been more successful than non-specific prevention e.g. with supplementary vitamin intake. The effectiveness of systemic chemotherapy decreases with the number of tumour cells present and with inherent drug resistance thus limiting palliative chemotherapy. stringent criteria for duration or intensity of palliative treatment are often missing. In contrast oncologic emergencies require immediate diagnostic work-up and therapeutic intervention. Salvage chemotherapy is useful if lack of host tolerance, non-compliance, and insufficient dose intensity have been excluded as causes of previous treatment failure in addition to analgesics, antibiotics, transfusions, and haematopoetic growth factors psychological support is needed along with palliative chemotherapy. The loss of treatment efficacy with increasing number of tumour cells probably also holds true for new treatments now still in their infancy such as differentiation, immune attack or gene transfer. Despite the obvious need for a shift from palliative treatment to prevention the establishment of quality standards for palliative chemotherapy remains a major goal.
近期癌症死亡率数据表明,资源应从晚期疾病新疗法的探索重新分配至预防策略。针对乙肝病毒(HBV)或其他致癌感染因子的疫苗接种,比非特异性预防(如补充维生素)更为成功。全身化疗的效果会随着肿瘤细胞数量的增加以及内在耐药性而降低,从而限制了姑息性化疗。通常缺乏关于姑息治疗持续时间或强度的严格标准。相比之下,肿瘤急症需要立即进行诊断检查和治疗干预。如果除了镇痛药、抗生素、输血和造血生长因子外,已排除宿主耐受性差、不依从和剂量强度不足等先前治疗失败的原因,挽救性化疗是有用的,同时姑息性化疗还需要心理支持。随着肿瘤细胞数量的增加,治疗效果的丧失可能同样适用于目前仍处于起步阶段的新疗法,如分化、免疫攻击或基因转移。尽管明显需要从姑息治疗转向预防,但建立姑息性化疗的质量标准仍是一个主要目标。